关于2021年限制性股票激励计划预留授予部分第二个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 证券代码：300015 股票简称：爱尔眼科 公告编号：2024-091 爱尔眼科医院集团股份有限公司 2022 年 3 月 25 日，公司召开第五届董事会第五十次会议和第五届监事会第二 十四次会议，审议通过《关于向激励对象授予预留部分限制性股票的议案》。公司独 立董事就上述事项出具独立意见，监事会对本次预留授予部分激励对象名单等相关 事项进行了核实。授予 1,146 名激励对象 1,555.8943 万股限制性股票，授予价格为 20.71 元/股。 经深圳证券交易所审核无异议、中国证券登记结算有限责任公司深圳分公司审 核确认，公司已于 2022 年 5 月 6 日完成了上述限制性股票的授予登记工作。 特别提示： 1、本次限制性股票解除限售股份上市流通时间为 2024 年 11 月 6 日； 2、本次符合解除限售条件的激励对象共计 1,068 名，均满足 100%解除限售条件，可解 除限售的限制性股票数量为 6,417,1 ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][3]. Core Views - The company's revenue growth has slowed due to weak consumer demand and healthcare policy impacts, with a reported revenue of 16.302 billion yuan for the first three quarters of 2024, a year-on-year increase of 1.58% [2][3]. - The net profit for the same period reached 3.452 billion yuan, reflecting an 8.5% year-on-year growth, while the third quarter saw a revenue decline of 0.68% year-on-year [2][3]. - The company demonstrates operational resilience with a net profit margin of 22.5% for the first three quarters of 2024, an increase of 0.56 percentage points year-on-year [3]. - The report adjusts the profit forecast for 2024-2026, estimating net profits of 3.499 billion, 3.988 billion, and 4.500 billion yuan respectively, down from previous estimates [3]. Financial Summary - For 2024, the expected revenue is 21.643 billion yuan, with a year-on-year growth of 6.3% [4]. - The projected net profit for 2024 is 3.499 billion yuan, reflecting a 4.2% increase year-on-year [4]. - The gross margin is expected to be 49.8% in 2024, slightly down from 50.8% in 2023 [4]. - The net margin is projected at 16.2% for 2024, compared to 16.5% in 2023 [4]. - The company's return on equity (ROE) is expected to be 16.5% in 2024, down from 17.8% in 2023 [4]. Cash Flow and Debt - The operating cash flow for 2023 is reported at 5.212 billion yuan, with projections of 6.483 billion yuan for 2024 [7]. - The total liabilities for 2023 stand at 10.162 billion yuan, with a projected decrease to 9.339 billion yuan by 2026 [6].

Investment Rating - The investment rating for the company is "Outperform the Market" [3][11]. Core Views - The company experienced a decline in revenue and profit in Q3 2024 due to macroeconomic factors, with revenue of 5.756 billion yuan, down 0.68% year-on-year, and net profit of 1.402 billion yuan, down 4.56% year-on-year. However, the company achieved a cumulative revenue of 16.302 billion yuan in the first three quarters of 2024, representing a year-on-year growth of 1.58% [1][4]. - The company is expanding its medical service network through orderly hospital acquisitions, having completed the acquisition of 87 hospitals this year, enhancing its operational management capabilities [1][10]. - The company maintains stable expense ratios, with a slight decline in gross margin to 51.02%, primarily due to a decrease in the revenue share of high-margin refractive and optical services [1][5]. Summary by Sections Financial Performance - In Q3 2024, the company reported revenue of 5.756 billion yuan and a net profit of 1.402 billion yuan, with year-on-year declines of 0.68% and 4.56%, respectively. The first three quarters of 2024 saw cumulative revenue of 16.302 billion yuan, up 1.58% year-on-year, and net profit of 3.452 billion yuan, up 8.50% year-on-year [1][4]. - The company has adjusted its revenue forecasts for 2024-2026 to 20.649 billion, 23.821 billion, and 27.241 billion yuan, respectively, with corresponding net profit forecasts of 3.534 billion, 4.262 billion, and 5.102 billion yuan [11][12]. Operational Expansion - The company completed the acquisition of 35 hospitals by the end of July 2024, with a total investment of 899 million yuan. This brings the total number of hospitals acquired this year to 87, indicating a robust expansion of its medical service network [1][10]. - The acquisition of the European chain eye hospital Clínica Baviera has resulted in an annualized net profit compound growth rate exceeding 25% [1][10]. Cost and Profitability Metrics - The company reported a gross margin of 51.02% in the first three quarters of 2024, a decrease of 0.91 percentage points year-on-year. The net profit margin improved to 21.17%, benefiting from increased investment income [1][5]. - The expense ratios for sales, management, financial, and R&D remained stable, with slight increases in sales and management expenses [1][5].

来源：公司年报、国金证券研究所 买入（维持评级） 业绩简评 2024 年 10 月 30 日，公司发布 2023 年第三季度报告。公司前三季 度公司实现收入 163.02 亿元，同比+1.58%；归母净利润 34.52 亿 元，同比+8.50%；实现扣非归母净利润 31.13 亿元，同比+0.26%。 单季度来看，2024Q3 公司实现收入 57.56 亿元，同比-0.68%；归 母净利润 14.02 亿元，同比-4.56%；实现扣非归母净利润 13.28 亿 元，同比-1.34%。 经营分析 经营指标健康，期间费用率平稳。期间费用率方面，2024Q3 公司 实现管理费用 13.65%（同比+0.66pct），实现销售费用率 10.06% （同比+0.05pct），实现研发费用率 1.43%（同比-0.10pct）。财务 费用率方面，2024Q3 公司实现财务费用率 0.40%（同比+0.46pct）， 经营活动现金流量净额为 42.99 亿元（同比-22.88%）。 医疗服务网络持续扩张，全国布局纵深发展。2024 年 7 月 29 日， 公司审议通过《关于收购虎门爱尔、运城爱尔等 35 家医院部分股 权的 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2024-088 《2024年第三季度报告》 监事会认为：董事会编制和审核公司 2024 年第三季度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2024 年第三季度经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 此项议案以 3 票同意，0 票反对，0 票弃权获得通过。 特此公告。 爱尔眼科医院集团股份有限公司监事会 2024 年 10 月 30 日 爱尔眼科医院集团股份有限公司 第六届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届监事会第十八 次会议于 2024 年 10 月 30 日以通讯表决的方式召开，会议通知于 2024 年 10 月 25 日以邮件方式送达，会议由监事会主席宁俊萍女士召集主持，应到监事 3 人， 实到监事 3 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合 法、有效。经审议，本次会议一致通过如下议案： ...

Event Overview - Aier Eye Hospital Group is celebrating its 15th anniversary of being listed on the stock market by launching a "15 Years of Listing, Giving Back to Investors" event [1] - The event aims to thank investors for their long-term trust and promote eye health awareness [1] - The event will provide exclusive benefits and activities for shareholders [1] Event Benefits - Shareholders will receive dedicated consultant services for consultation, appointment, and expert registration [1] - Exclusive discounts on optometry and glasses for myopia, hyperopia, and presbyopia [1] - Special discounts on refractive surgery for myopia correction [1] - Dynamic shareholder-exclusive benefits and networking activities will be offered [1] Event Details - The event is open to all shareholders, including current, previous, and future investors [2] - Initially, the event will be implemented in 33 provincial capital hospitals, with plans to expand coverage gradually [2] - The event will be executed on a long-term basis starting from the announcement date [2] - Participation can be done by scanning a QR code provided in the announcement [2] Contact Information - Contact persons: Li Jinzhou, Li Mi [3] - Phone: 0731-85136739 [3] - Email: zhengquanbu@yeah.net [3] - More details can be found on the "Aier Eye Hospital Investor Relations" official WeChat account (AierIR) on October 30, 2024 [3]

Financial Performance - Revenue for the third quarter was RMB 5.756 billion, a decrease of 0.68% year-over-year[3] - Net profit attributable to shareholders was RMB 1.402 billion, down 4.56% year-over-year[3] - Total revenue for the period reached RMB 16.30 billion, a slight increase from RMB 16.05 billion in the previous year[19] - Net profit attributable to parent company shareholders was RMB 3.45 billion, up from RMB 3.18 billion in the same period last year[20] - Basic earnings per share increased to RMB 0.3746 from RMB 0.3453 year-over-year[21] - Total comprehensive income for the period was RMB 3.66 billion, compared to RMB 3.52 billion in the previous year[21] Cash Flow and Operating Activities - Operating cash flow for the first nine months was RMB 4.299 billion, a decrease of 22.88% year-over-year[3] - Operating cash flow from sales and services was RMB 16.06 billion, up from RMB 15.66 billion in the previous year[22] - Operating cash inflow totaled 16,292,338,112.42 RMB, a slight increase from 15,958,709,458.14 RMB in the previous period[23] - Operating cash outflow increased to 11,993,575,517.60 RMB from 10,384,336,600.64 RMB, primarily driven by higher payments for goods, services, and employee compensation[23] - Net cash flow from operating activities decreased to 4,298,762,594.82 RMB from 5,574,372,857.50 RMB[23] - Net cash flow from investing activities was -2,419,173,893.02 RMB, compared to -2,373,367,243.03 RMB in the previous period[23] - Net cash flow from financing activities was -3,114,958,510.84 RMB, a significant decrease from -2,414,019,859.71 RMB[24] - Cash and cash equivalents at the end of the period were 4,852,300,253.65 RMB, down from 6,793,419,319.65 RMB[24] - Payments for employee compensation increased to 4,974,774,418.08 RMB from 4,206,346,978.03 RMB[23] - Payments for taxes and fees rose to 838,522,341.58 RMB from 761,631,256.67 RMB[23] - Cash received from investments decreased to 974,418,665.10 RMB from 1,100,936,682.02 RMB[23] - Cash paid for acquisitions of subsidiaries and other business units increased to 1,856,519,537.87 RMB from 1,102,763,856.82 RMB[23] Assets and Liabilities - Total assets increased by 9.25% to RMB 32.979 billion compared to the end of the previous year[3] - Fixed assets increased by 31.85% to RMB 5.095 billion due to new hospital acquisitions and subsidiary openings[6] - Goodwill increased by 33.43% to RMB 8.717 billion due to cash payments for non-controlling equity acquisitions[6] - Total assets increased from 30,186,619,945.52 yuan to 32,979,353,178.25 yuan[17] - Fixed assets increased from 3,864,318,150.30 yuan to 5,094,963,750.91 yuan[16] - Goodwill increased from 6,532,827,966.38 yuan to 8,716,742,506.98 yuan[17] - Short-term borrowings decreased from 850,366,666.67 yuan to 700,312,500.00 yuan[17] - Accounts payable increased from 1,809,292,666.97 yuan to 2,234,546,252.26 yuan[17] - Total current liabilities increased from 6,011,230,680.34 yuan to 6,681,450,808.73 yuan[17] - Total liabilities increased to RMB 11.44 billion from RMB 10.16 billion at the beginning of the period[18] - Total equity rose to RMB 21.54 billion, compared to RMB 20.02 billion at the start of the period[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 372,778[9] - Aier Medical Investment Group holds 34.33% of the shares, totaling 455,735,194 shares[9] - Chen Bang holds 15.48% of the shares, totaling 210,068,746 shares, with 1,082,843,918 shares under lock-up[9] - Li Li holds 3.46% of the shares, totaling 101,513,370 shares, with 242,261,245 shares under lock-up[9] - Hong Kong Securities Clearing Company holds 2.29% of the shares[9] - China Bank - Huabao CSI Medical ETF holds 1.68% of the shares[9] - Industrial and Commercial Bank of China - China Europe Medical Health Mixed Fund holds 1.56% of the shares, totaling 145,831,330 shares[10] - Industrial and Commercial Bank of China - E Fund ChiNext ETF holds 1.26% of the shares, totaling 117,632,766 shares[10] - Guo Hongwei holds 1.07% of the shares, totaling 100,000,000 shares[10] - Industrial and Commercial Bank of China - Huatai-PineBridge CSI 300 ETF holds 0.95% of the shares, totaling 88,476,005 shares[10] - Total restricted shares at the end of the period: 1,422,010,383 shares[14] Expenses and Investments - Financial expenses surged by 120.03% to RMB 140.818 million due to increased lease interest expenses and exchange rate fluctuations[7] - Investment income rose by 431.10% to RMB 148.922 million due to increased returns from financial products[7] - R&D expenses decreased to RMB 233.15 million from RMB 246.03 million year-over-year[20] - Sales expenses increased to RMB 1.64 billion, up from RMB 1.61 billion in the same period last year[20] - Cash paid for acquisitions of subsidiaries increased by 68.35% to RMB 1.857 billion[8] - Dividends and interest payments increased by 82.35% to RMB 1.649 billion[8] Monetary Funds - Monetary funds decreased from 6,099,082,253.65 yuan to 4,855,500,253.65 yuan[16]

公司《2024 年第三季度报告》的编制程序符合法律、行政法规和中国证监 会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在虚假记 载、误导性陈述或者重大遗漏。 证券代码：300015 股票简称：爱尔眼科 公告编号：2024-087 爱尔眼科医院集团股份有限公司 第六届董事会第二十九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届董事会第二十九 次会议于 2024 年 10 月 30 日以通讯表决方式召开，会议通知于 2024 年 10 月 25 日以邮件方式送达，会议由董事长陈邦先生召集。应到董事 7 人，实到董事 7 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合法、有效。 经审议，本次会议一致通过如下议案： 《2024 年第三季度报告》 该议案已经审计委员会审议通过。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年第 三季度报告》。 此项议案以 7 票同意、0 票反对、0 票弃权获得通过。 特此公告。 爱尔眼科医院集团股份有限 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2024-085 爱尔眼科医院集团股份有限公司 关于公司实际控制人进行股票质押式回购交易及部分股份 解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或者重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）近日接到公司实际控 制人陈邦先生函告，获悉陈邦先生所直接持有本公司的部分股份进行股票质押式 回购交易及部分股份解除质押，具体事项如下： 一、股东股份质押及解除质押的基本情况 | 股东 | 是否为第一大 股东及一致行 | 本次解除质 | 占其所 持股份 | 占公司总股本比 | 起始日 | | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 押股数（股） | | 例 | | | | | | | | 动人 | | 比例 | | | | | | | | 陈邦 | 是 | 130,000,000 | 9.00% | 1.39% | 2023 11 月 | 年 9 | 2024 10 | 年 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2024-083 爱尔眼科医院集团股份有限公司 关于举办第六届"全国爱尔眼科医院投资者接待日"活动的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 2019 年 10 月 14 日，爱尔眼科医院集团股份有限公司（以下简称"公司"） 第四届董事会第五十一次会议审议通过了《全国爱尔眼科医院投资者接待日制 度》，定于每年 10 月 30 日（公司上市周年日），由全国各地爱尔眼科医院的 CEO、院长等医院管理层接待来访的投资者，解答投资者关心的各类问题，倾听 投资者的意见和建议。历届活动均取得了积极效果，有效增进了投资者对公司一 线基本面的直观了解，同时更多投资者成为眼健康知识的受益者和传播者。 为进一步汇聚市场力量、推进公司高质量发展，公司定于 2024 年 10 月 30 日举办第六届"全国爱尔眼科医院投资者接待日"活动，公开、透明地向资本市 场展示公司及各地医院的发展情况，帮助投资者更好地了解公司和行业，欢迎海 内外投资者报名参加本次活动（包括但不限于本公司股东）。 本次活动有关事项通知如下： 一、参与医 ...